1. Home
  2. NNVC vs LYRA Comparison

NNVC vs LYRA Comparison

Compare NNVC & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NNVC
  • LYRA
  • Stock Information
  • Founded
  • NNVC 2005
  • LYRA 2005
  • Country
  • NNVC United States
  • LYRA United States
  • Employees
  • NNVC N/A
  • LYRA N/A
  • Industry
  • NNVC Biotechnology: Pharmaceutical Preparations
  • LYRA Medical/Dental Instruments
  • Sector
  • NNVC Health Care
  • LYRA Health Care
  • Exchange
  • NNVC Nasdaq
  • LYRA Nasdaq
  • Market Cap
  • NNVC 17.7M
  • LYRA 18.0M
  • IPO Year
  • NNVC N/A
  • LYRA 2020
  • Fundamental
  • Price
  • NNVC $1.35
  • LYRA $0.18
  • Analyst Decision
  • NNVC Strong Buy
  • LYRA Buy
  • Analyst Count
  • NNVC 1
  • LYRA 5
  • Target Price
  • NNVC $6.50
  • LYRA $4.50
  • AVG Volume (30 Days)
  • NNVC 130.2K
  • LYRA 2.0M
  • Earning Date
  • NNVC 11-22-2024
  • LYRA 11-12-2024
  • Dividend Yield
  • NNVC N/A
  • LYRA N/A
  • EPS Growth
  • NNVC N/A
  • LYRA N/A
  • EPS
  • NNVC N/A
  • LYRA N/A
  • Revenue
  • NNVC N/A
  • LYRA $1,471,000.00
  • Revenue This Year
  • NNVC N/A
  • LYRA $13.99
  • Revenue Next Year
  • NNVC N/A
  • LYRA N/A
  • P/E Ratio
  • NNVC N/A
  • LYRA N/A
  • Revenue Growth
  • NNVC N/A
  • LYRA 3.37
  • 52 Week Low
  • NNVC $1.00
  • LYRA $0.18
  • 52 Week High
  • NNVC $3.59
  • LYRA $6.79
  • Technical
  • Relative Strength Index (RSI)
  • NNVC 42.61
  • LYRA 30.57
  • Support Level
  • NNVC $1.44
  • LYRA $0.26
  • Resistance Level
  • NNVC $1.58
  • LYRA $0.28
  • Average True Range (ATR)
  • NNVC 0.08
  • LYRA 0.02
  • MACD
  • NNVC -0.01
  • LYRA -0.01
  • Stochastic Oscillator
  • NNVC 26.79
  • LYRA 0.35

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Share on Social Networks: